GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ONCT
Oncternal is an oncology company developing drugs to treat difficult-to-treat cancers. Its stock price is highly volatile and driven by news of clinical trials. The chart reflects the binary risks and hopes associated with new drug development.
Share prices of companies in the market segment - General oncology therapy
Oncternal Therapeutics is an oncology company developing targeted therapies for the treatment of blood cancers and solid tumors. We've classified it in the "General Oncology" category. The chart below shows how investors value biotech companies operating in this broad and competitive field.
Broad Market Index - GURU.Markets
Oncternal Therapeutics is an oncology company developing targeted therapies for the treatment of blood cancers and solid tumors. We've classified it in the "General Oncology" category. The chart below shows how investors value biotech companies operating in this broad and competitive field.
Change in the price of a company, segment, and market as a whole per day
ONCT - Daily change in the company's share price ONCT
Oncternal Therapeutics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its oncology drugs.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for cancer and rare diseases. Oncology is a volatile sector. The chart below reflects average fluctuations in this industry, providing context for evaluating ONCT stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Oncternal Therapeutics is a biotech company developing drugs to treat cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ONCT
Oncternal Therapeutics' year-to-date performance is a story about its oncology drug development. Its 12-month market cap is entirely dependent on clinical trial data for its lead candidate, which targets ROR1. Success in treating blood cancers and solid tumors could be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - General oncology therapy
As an early-stage biotech, Oncternal is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oncternal Therapeutics, a clinical-stage oncology company, develops targeted therapies for the treatment of difficult-to-treat cancers. Its year-over-year market capitalization is a classic biotech story, where clinical data is king.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ONCT
Oncternal is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its targeted drugs triggers an immediate and strong investor reaction.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of difficult-to-treat cancers, particularly lymphoma and prostate cancer. The chart below shows the overall dynamics in the oncology sector, reflecting the ongoing search for new therapeutic approaches to combat this disease.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Early-stage biotech stocks are a venture bet on science. The chart below shows investors' overall risk appetite. Is Oncternal Therapeutics moving at an extreme amplitude, amplifying market movements, as is typical for such stories?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ONCT
The weekly performance of Oncternal, an oncology biotech, reflects the search for new treatments for blood cancer. Share prices are responding to clinical trial data for their targeted drugs and to overall sentiment in the biotech sector.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Oncternal Therapeutics develops targeted drugs for the treatment of difficult-to-treat cancers. This chart helps separate its own news-driven dynamics from the overall fluctuations in the oncology sector, showing how the market views its pipeline and its chances of success.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Oncternal Therapeutics is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Oncternal is stuck in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
ONCT - Market capitalization of the company ONCT
Oncternal's market capitalization tells the story of a biotech company developing targeted therapies for difficult-to-treat cancers. Its volatile chart reflects progress in clinical trials. Its price action reflects investors' assessment of the scientific potential of its drugs and their potential to become a new standard of care.
ONCT - Share of the company's market capitalization ONCT within the market segment - General oncology therapy
Oncternal Therapeutics is an oncology company targeting rare cancers. Its share of the market capitalization of its biotech segment is a function of the progress of its clinical trials. The chart below shows how its share changes, reflecting investor expectations for the success of its drugs.
Market capitalization of the market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage biotech company developing drugs to treat difficult-to-treat cancers. The chart below shows the overall market capitalization of the oncology sector. Its dynamics provide the backdrop against which Oncternal conducts its research, striving to help patients with limited options.
Market capitalization of all companies included in a broad market index - GURU.Markets
Oncternal Therapeutics is a clinical-stage biotech company developing drugs to treat difficult-to-treat cancers. Its market cap reflects the hope of patients and investors' faith in its science. Its volatility on the overall chart is typical of biotech, where clinical trial data is everything.
Book value capitalization of the company, segment and market as a whole
ONCT - Book value capitalization of the company ONCT
Oncternal Therapeutics' foundation is its investment in clinical trials for drugs to treat difficult-to-treat cancers, such as mantle cell lymphoma. This is a real, scientific foundation focused on rare oncological diseases. How has this biotech asset evolved? The chart below shows its dynamics.
ONCT - Share of the company's book capitalization ONCT within the market segment - General oncology therapy
Oncternal Therapeutics develops targeted drugs for cancer treatment, which requires research laboratories. The chart shows the share of these science-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation of its scientific activities.
Market segment balance sheet capitalization - General oncology therapy
Oncternal, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Oncternal Therapeutics' book value is its patent portfolio and clinical trial data for drugs treating difficult-to-treat cancers. The company's assets are the capitalized results of its R&D. The chart below shows how this biotech compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ONCT
Oncternal Therapeutics develops targeted cancer therapies. Its balance sheet represents the value of its intellectual property. Its market capitalization represents the hope that its drugs will accurately target cancer cells. The MvsBCap_Co chart shows how investors' confidence in the success of its clinical programs fluctuates.
Market to book capitalization ratio in a market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage biotech company developing drugs for the treatment of difficult-to-treat cancers. Its market valuation in the chart is based on the progress of its clinical programs and investor expectations for their ultimate success.
Market to book capitalization ratio for the market as a whole
Oncternal Therapeutics, an oncology company in clinical development, is a company whose market capitalization reflects investor expectations for a successful drug. This chart shows how high the premium for a potential breakthrough in biotech is compared to the market average.
Debts of the company, segment and market as a whole
ONCT - Company debts ONCT
Oncternal Therapeutics, a clinical-stage oncology company, uses capital to fund the development of its targeted therapies. This chart shows how the company manages its resources to advance its research through the complex and lengthy clinical trial process to eventual approval.
Market segment debts - General oncology therapy
Oncternal Therapeutics is a clinical-stage biotech focused on rare cancers. Like its peers, it has no sales revenue and relies entirely on equity capital to fund its research. This chart illustrates the industry's typical financial model, with minimal to no debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ONCT
Oncternal Therapeutics is a clinical-stage oncology company. It has no commercial products yet, and all its activities are funded by investors. This chart shows the extent to which the company uses debt to conduct clinical trials. It directly reflects the level of financial risk for shareholders in anticipation of successful results.
Market segment debt to market segment book capitalization - General oncology therapy
Oncternal Therapeutics develops targeted drugs for the treatment of difficult-to-treat cancers. Oncology R&D is a marathon that requires enormous financial resources. The chart shows how aggressively the biotech sector uses debt to fund research, providing context for assessing Oncternal's financial sustainability.
Debt to book value of all companies in the market
Oncternal Therapeutics, a clinical-stage oncology company, develops targeted therapies, a lengthy and capital-intensive process. This chart, reflecting the overall market debt burden, provides context for assessing its financial strategy. It helps understand how the company raises capital to fund its expensive research.
P/E of the company, segment and market as a whole
P/E - ONCT
Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of difficult-to-treat cancers. This chart shows how the market values its pipeline. This value is based on clinical trial progress and the potential of its drugs in oncology.
P/E of the market segment - General oncology therapy
This chart for biotech companies serves as a benchmark for Oncternal Therapeutics. It reflects generally high valuations based on hopes for a breakthrough. Comparison with this chart helps understand how the market values Oncternal's pipeline of targeted cancer therapies and whether it believes they have commercial potential if clinical trials are successful.
P/E of the market as a whole
Oncternal Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of oncological diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. The overall market sentiment reflected in this chart is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ONCT
For Oncternal Therapeutics, a biopharmaceutical company focused on treating difficult-to-treat cancers, this chart demonstrates market expectations for its clinical developments. It reflects investor confidence in the potential of its targeted therapies and their ability to become new standards of care.
%20P%2FE%20ONCT&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ONCT&v=1772555031706 "Chart of the company's future (projected) P/E ONCT")
Future (projected) P/E of the market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for difficult-to-treat cancers such as mantle cell lymphoma and prostate cancer. This chart shows forecasts for the oncology sector, allowing for a comparison of how the market perceives the potential of Oncternal's key candidates in their specific niches.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772555031856 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Oncternal Therapeutics, Inc. is a biopharmaceutical company developing targeted therapies for cancer treatment. Its valuation depends on the success of its clinical programs. This overall risk appetite chart shows how willing investors are to support science-based companies working on personalized cancer treatments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772555031893 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ONCT
Oncternal Therapeutics is a clinical-stage oncology company developing targeted therapies for cancers with high unmet needs. Its financial results reflect clinical trial expenses. This chart shows the cost of developing drugs for difficult-to-treat cancers.
Profit of companies in the market segment - General oncology therapy
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. This chart, which shows profitability in the oncology sector, demonstrates the importance of finding new targets. Their drugs target pathways that play a key role in cancer cell growth and survival, particularly in blood cancers.
Overall market profit
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. Its future depends on the success of its clinical programs. This total market return chart reflects the investment environment, which is critical for development-stage companies, as they continually require capital for research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ONCT
Oncternal Therapeutics is a biotechnology company developing targeted therapies for the treatment of difficult-to-treat cancers, including blood cancers and solid tumors. This chart represents analyst consensus forecasts for clinical trial success and the potential of its lead candidates in the highly competitive oncology market.
%20profit%20of%20the%20company%20ONCT&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ONCT&v=1772555032062 "Graph of future (projected) profit of the company ONCT")
Future (predicted) profit of companies in the market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. Its future depends on the success of clinical trials. This chart for the oncology sector reflects the general confidence of investors that new approaches to cancer treatment will lead to the development of effective drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772555032146 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Oncternal Therapeutics is developing a targeted therapy for cancer treatment. Its future depends on success in clinical trials. The overall economic climate, illustrated by this chart, affects the availability of capital for biotech companies and their ability to fund expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772555032229 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ONCT
Oncternal Therapeutics is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers. For a clinical-stage company, this chart is key. It shows how investors evaluate the potential of its lead candidates, betting on future sales if trials are successfully completed and approval is achieved.
P/S market segment - General oncology therapy
Oncternal Therapeutics is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers. The clinical-stage company's valuation is based on the future potential of its targeted therapies. This chart, which displays the average valuation in the oncology industry, provides context for understanding how the market values Oncternal's pipeline.
P/S of the market as a whole
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments with high unmet needs. This chart, which reflects revenue estimates for real businesses, highlights that Oncternal's value stems from investors' faith in its scientific developments and potential to create new standards of oncology treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ONCT
Oncternal Therapeutics is a clinical-stage biotech company focused on developing targeted therapies for difficult-to-treat cancers. This chart reflects investors' hopes that its candidates will successfully complete clinical trials and offer new treatment options for patients with limited treatment options.
%20P%2FS%20ONCT&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ONCT&v=1772555032389 "The graph of the company's future (projected) P/S ONCT")
Future (projected) P/S of the market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for cancers with high unmet medical needs. This chart reflects average revenue expectations in the oncology sector. It allows investors to assess the market perception of the potential of Oncternal's oncology portfolio.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772555032395 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. This chart shows investor expectations for revenue growth. The company's progress in clinical trials and its ability to offer new options for patients with aggressive tumors contribute to the overall belief in the victory over cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772555032426 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ONCT
This chart illustrates the revenue of Oncternal Therapeutics, a clinical-stage biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. Its revenue is generated through collaboration fees with other companies, reflecting research progress rather than commercial sales.
Sales of companies in the market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage oncology company developing targeted therapies for cancers with high unmet needs. This chart reflects revenue in the oncology sector. The company's developments target difficult-to-treat blood cancers and solid tumors, and its success could offer new treatment options for thousands of patients.
Overall market sales
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for the treatment of cancer. Its development depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and the funding of advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ONCT
Oncternal Therapeutics is a biotechnology company developing targeted therapies for the treatment of difficult-to-treat cancers. The company's future revenue depends on the success of its clinical trials. The chart reflects analyst expectations for the commercial potential of its oncology portfolio.
%20sales%20of%20the%20company%20ONCT&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ONCT&v=1772555032742 "Schedule of future (projected) sales of the company ONCT")
Future (projected) sales of companies in the market segment - General oncology therapy
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for the treatment of difficult-to-treat cancers such as mantle cell lymphoma and prostate cancer. This chart shows the forecast for the entire oncology market, where Oncternal aims to offer new treatment options for patients with limited therapeutic options.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772555032754 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Oncternal Therapeutics is a clinical-stage biotech company developing targeted therapies for difficult-to-treat cancers. Its valuation depends on the success of clinical trials. This graph, reflecting the overall sentiment in the biotech sector, impacts the company's ability to attract funding to continue its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772555032805 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ONCT
Oncternal Therapeutics is a biotech company developing targeted drugs for the treatment of difficult-to-treat cancers. While in clinical trials, it incurs significant R&D expenses. This chart shows its net losses, which represent investments in developing new therapeutic options for cancer patients.
Market segment marginality - General oncology therapy
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments with high unmet medical need. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it to understand the potential of their targeted oncology drugs.
Market marginality as a whole
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for the treatment of difficult-to-treat cancers, particularly blood cancer and prostate cancer. This overall profitability curve is irrelevant to them. Their value depends solely on the success of their clinical programs and the potential of their drugs to become a new standard of care.
Employees in the company, segment and market as a whole
Number of employees in the company ONCT
Oncternal Therapeutics is a clinical-stage biotech company developing targeted cancer therapies. It operates with a small, focused team. This chart demonstrates a lean R&D management model, where many functions are outsourced to reduce costs.
Share of the company's employees ONCT within the market segment - General oncology therapy
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. This chart reflects its share of the total number of researchers in this niche area of oncology. This growth reflects progress in clinical trials and the expansion of the scientific team working on the development of life-saving drugs.
Number of employees in the market segment - General oncology therapy
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. This chart shows employment trends in the oncology sector. Fluctuations in the hiring of scientists and clinicians are directly related to clinical trial results, which are a key factor in determining the future of these companies.
Number of employees in the market as a whole
Oncternal Therapeutics is a biotech company focused on treating difficult-to-treat cancers. Its future depends on the success of its clinical programs and partnerships. Overall economic stability, reflected in this chart, is important for raising capital and ensuring sustainable funding throughout all stages of drug development.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ONCT (ONCT)
Oncternal Therapeutics is a clinical-stage biotechnology company focused on drugs for the treatment of difficult-to-treat cancers. Its staff consists of scientists and clinical trial managers. This chart shows that market value is completely divorced from current revenue. Value per employee reflects the market valuation of the company's intellectual property and the potential of its lead drug candidates.
%20of%20the%20company%20ONCT%20(ONCT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ONCT-ONCT&v=1772555033220 "Chart of market capitalization per employee (in thousands of dollars) of the company ONCT (ONCT)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Oncternal Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of difficult-to-treat cancers. Like many companies in this sector, its value is determined by the potential of its clinical programs. This chart shows the market valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772555033308 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The chart shows their scientific potential assessment. It reflects how the market views their pipeline of developments, where the contribution of a small team of scientists can lead to the creation of a sought-after drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772555033333 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ONCT (ONCT)
Oncternal Therapeutics is a clinical-stage biotech company specializing in the development of targeted therapies for difficult-to-treat cancers. This is pure R&D. This chart reflects the cost of science: it shows the amount of capital the company "burns" (invests) for each of its highly qualified scientists.
%20Chart%20ONCT%20(ONCT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ONCT-ONCT&v=1772555033398 "Company Profit Per Employee (in thousands of dollars) Chart ONCT (ONCT)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Oncternal Therapeutics is a clinical-stage biotech company developing drugs for the treatment of difficult-to-treat cancers. Like most R&D companies, this metric is negative. It reflects targeted investments in research and clinical trials rather than operating losses.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772555033418 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Oncternal Therapeutics is a clinical-stage biotech company specializing in oncology. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per team of scientists developing a new drug through expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772555033443 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ONCT (ONCT)
Oncternal Therapeutics is a biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. This chart reflects the company's progress in commercializing its developments. Revenue growth at this stage is likely due to payments from partners following clinical trial successes.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ONCT-ONCT&v=1772555033470 "Sales chart per company employee ONCT (ONCT)")
Sales per employee in the market segment - General oncology therapy
Oncternal Therapeutics is a biotech company focused on treating rare and difficult-to-treat cancers. While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is in monetizing their developments per scientist.
Sales per employee for the market as a whole
Oncternal Therapeutics (ONCT) is a clinical-stage biotech company specializing in cancer treatment. The company currently has no approved products on the market. This chart illustrates a classic R&D scenario: a team of highly qualified scientists and physicians is working on developing future drugs. Revenue (if any) comes from partnerships.
Short shares by company, segment and market as a whole
Shares shorted by company ONCT (ONCT)
Oncternal Therapeutics is a biotech company specializing in cancer treatment. Its success depends on its lead drug candidate. The bearish sentiment shown in this chart is a direct bet by investors that its key drug will fail to prove effective in crucial clinical trials and will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ONCT-ONCT&v=1772555033514 "Short Shares Chart for the Company ONCT (ONCT)")
Shares shorted by market segment - General oncology therapy
Oncternal Therapeutics is a biopharmaceutical company focused on developing new cancer treatments. Their success depends on breakthroughs in oncology. This indicator measures the total volume of short positions across the entire oncology biotech sector. It shows how much investors generally believe in the success of new drugs in the industry or whether they fear clinical failures and regulatory hurdles.
Shares shorted by the overall market
Oncternal (ONCT) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ONCT will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ONCT (ONCT)
This chart for Oncternal is a binary bet in oncology. The company is betting on its blood cancer drug Zilovertamab. "Overbought" (above 70) occurs on positive Phase 2 data. A Phase 3 failure or an FDA requirement for new trials will immediately drop the oscillator to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ONCT-ONCT&v=1772555033591 "RSI 14 indicator chart for the company's stock ONCT (ONCT)")
RSI 14 Market Segment - General oncology therapy
Oncternal (ONCT) is a biotech company focused on developing drugs to treat difficult-to-treat cancers, such as mantle cell lymphoma. This chart measures overall sentiment in the Oncology sector. It helps distinguish ONCT's trial successes from overall "overheating" or "overselling" across the biotech sector.
RSI 14 for the overall market
For Oncternal, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ONCT (ONCT)
Oncternal (ONCT) is a clinical-stage oncology company developing targeted therapies for difficult-to-treat cancers (e.g., lymphoma). This chart shows the average target price. It reflects analysts' speculative valuations of its leading candidates and their chances of success in key clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ONCT-ONCT&v=1772555033706 "A chart showing analyst consensus forecasts for the expected stock price. ONCT (ONCT)")
The difference between the consensus estimate and the actual stock price ONCT (ONCT)
Oncternal (ONCT) is a biotech company developing targeted therapies for difficult-to-treat cancers (mantle cell lymphoma, prostate cancer). This chart shows the difference between the market valuation and the consensus estimate. It highlights the potential (and risks) analysts see in their oncology R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ONCT-ONCT&v=1772555033709 "A chart showing the difference between the consensus forecast and the actual stock price. ONCT (ONCT)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Oncternal is an R&D biotech company developing drugs for the treatment of difficult-to-treat cancers (mantle cell lymphoma, prostate cancer). This chart reflects analysts' overall expectations for the *entire* oncology sector. It shows whether experts believe junior R&D companies can succeed in this complex field.
Analysts' consensus forecast for the overall market share price
Oncternal Therapeutics (ONCT) is a clinical-stage biopharmaceutical company focused on treating difficult-to-treat cancers. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ONCT
Oncternal is a biotech cancer hunter. It's an R&D company developing targeted therapies (small molecules, CAR-T) for the treatment of rare cancers (mantle cell lymphoma) and blood cancers. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of approval.
AKIMA Market Segment Index - General oncology therapy
Oncternal Therapeutics (ONCT) is a general oncology biotech targeting difficult-to-treat cancers. Their R&D focuses on the ROR1 target, which is present in many aggressive tumors. This chart compares their composite index to the sector, showing how their ROR1-targeted strategy compares to others.
The AKIM Index for the overall market
Oncternal Therapeutics is an oncology company developing therapies targeting novel biological pathways (ROR1, TNB). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to overall economic trends and competition.
